Trial Profile
Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Decitabine (Primary)
- Indications Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 06 Feb 2024 Planned End Date changed from 30 Oct 2026 to 30 Oct 2027.
- 27 Dec 2019 Planned End Date changed from 1 Oct 2027 to 30 Oct 2026.
- 27 Dec 2019 Planned primary completion date changed from 1 Oct 2026 to 30 Oct 2026.